Related Experiment Video
Updated: Jun 6, 2025
07:00
Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine
Published on: February 26, 2019
9.4K
Compounded GLP-1 and Dual GIP/GLP-1 Receptor Agonists: A Statement from the American Diabetes Association
Joshua J Neumiller1, Mandeep Bajaj2, Raveendhara R Bannuru3
1Department of Pharmacotherapy, Washington State University, Spokane, WA.
Diabetes Care
|December 2, 2024
Summary
Glucagon-like peptide 1 receptor agonists (GLP-1 RA) and dual GIP/GLP-1 RAs are facing shortages, leading to safety concerns with compounded versions. This statement guides safe use of these important diabetes and obesity medications.
Area of Science:
- Endocrinology
- Pharmacology
- Metabolic Diseases
Background:
- Glucagon-like peptide 1 receptor agonist (GLP-1 RA) and dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 RA (GIP/GLP-1 RA) medications are increasingly prescribed for type 2 diabetes and obesity.
- Substantial increases in demand have led to temporary shortages of these crucial pharmacotherapies.
- Product shortages have prompted the marketing of compounded formulations, raising significant concerns regarding safety, quality, and efficacy.
Purpose of the Study:
- To provide guidance for healthcare professionals and individuals with diabetes and/or obesity regarding medication unavailability.
- To promote optimal patient care and safe medication use during shortages of GLP-1 RA and GIP/GLP-1 RA therapies.
- To address the ongoing marketing of compounded formulations despite potential risks.
Main Methods:
- This is a statement from the American Diabetes Association.
- The statement synthesizes current information on GLP-1 RA and GIP/GLP-1 RA therapies, shortages, and compounded products.
- It offers recommendations for navigating medication unavailability and ensuring patient safety.
Main Results:
- Shortages of GLP-1 RA and GIP/GLP-1 RA medications have occurred due to high demand.
- Compounded formulations are being marketed, posing potential risks to patient safety, quality, and treatment efficacy.
- These compounded products continue to be promoted even as shortages potentially resolve.
Conclusions:
- Healthcare professionals and patients need clear guidance to manage shortages of GLP-1 RA and GIP/GLP-1 RA medications.
- Prioritizing safety, quality, and efficacy is essential when considering alternative or compounded therapies.
- The American Diabetes Association aims to support informed decision-making for optimal diabetes and obesity management.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
298
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
298
01:23Dipeptidyl Peptidase 4 Inhibitors
171
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
171
01:06Oral Hypoglycemic Agents: Glinides
139
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
139
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
172
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
172
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
159
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
159
01:17Oral Hypoglycemic Agents: Sulfonylureas
187
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
187